# Diagnostic performance of a point-of-care molecular system for the detection of SARS-CoV-2 in Peru

**Authors:** Zully M. Puyén, Roger Araujo-Castillo, Jorge Giraldo, Karina Gutierrez, Nancy Rojas-Serrano, Zully M. Puyén, Roger Araujo-Castillo, Jorge Giraldo, Karina Gutierrez, Nancy Rojas-Serrano

PMC · DOI: 10.17843/rpmesp.2024.411.13046 · Revista Peruana de Medicina Experimental y Salud Publica · 2024-03-26

## TL;DR

This study evaluated a rapid test for SARS-CoV-2 in Peru and found it highly accurate compared to a standard PCR test.

## Contribution

The study provides empirical validation of the Xpert®Xpress SARS-CoV-2 test's performance in a Peruvian population.

## Key findings

- The test showed 98.70% overall concordance with the reference PCR test.
- It had 100% sensitivity and 96.15% relative specificity for SARS-CoV-2 detection.
- The test also demonstrated 100% analytical specificity against other respiratory viruses.

## Abstract

The present study assessed the diagnostic performance of the Xpert®Xpress SARS-CoV-2 test in comparison with the Charité protocol real-time RT PCR for the detection of SARS-CoV-2 in Peruvian patients. This was a diagnostic test study that included 100 nasal and pharyngeal swab samples. We obtained an overall concordance of 98.70% (95%CI: 92.98-99.97), with a kappa coefficient of 0.97 (95%CI: 0.86-1.00) and sensitivity and relative specificity rates of 100% and 96.15%, respectively. Additionally, the percentage of the area under the ROC curve was 98.08% in both cases, and an analytical specificity rate of 100% was obtained for the different respiratory viruses evaluated. In conclusion, the Xpert®Xpress SARS-CoV-2 test, by using nasal and pharyngeal swab samples, was highly sensitive and specific, and the kappa coefficient showed an excellent correlation when compared to the reference test.

En el presente estudio se estimó el rendimiento diagnóstico de la prueba Xpert®Xpress SARS-CoV-2 en comparación con la RT PCR en tiempo real-protocolo Charité, para la detección de SARS-CoV-2 en pacientes peruanos. Se trató de un diseño de prueba diagnóstica que incluyó 100 muestras de hisopado nasal y faríngeo. Se obtuvo una concordancia global de 98,70% (IC95%: 92,98-99,97), con un coeficiente kappa de 0,97 (IC95%: 0,86-1.00); se estimó una sensibilidad y especificad relativa de 100% y 96,15%, respectivamente. Adicionalmente, el porcentaje del área bajo la curva ROC fue 98,08% en ambos casos y se obtuvo una especificidad analítica del 100% para los diferentes virus respiratorios evaluados. En conclusión, la prueba Xpert®Xpress SARS-CoV-2 a partir de muestras de hisopado nasal y faríngeo fue altamente sensible y específica, así mismo el coeficiente kappa mostró una excelente correlación, al compararla con la prueba de referencia.

## Linked entities

- **Diseases:** SARS-CoV-2 (MONDO:0100096)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Diseases:** SARS-CoV-2 (MESH:D000086382), infectious agents (MESH:D003141)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11149772/full.md

## References

21 references — full list in the complete paper: https://tomesphere.com/paper/PMC11149772/full.md

---
Source: https://tomesphere.com/paper/PMC11149772